Imperial College London
Portrait Picture

ProfessorJamesBarlow

Business School

Chair in Technology and Innovation Management
 
 
 
//

Contact

 

+44 (0)20 7594 5936j.barlow Website CV

 
 
//

Assistant

 

Mrs Lorraine Sheehy +44 (0)20 7594 9173

 
//

Location

 

Room 197EBusiness School BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@techreport{Barlow:2019,
author = {Barlow, J and Tan, S},
publisher = {Policy Innovation Research Unit},
title = {Challenges in addressing Anti-Microbial Resistance (AMR) through Drug-related Solutions},
url = {https://piru.ac.uk/},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - RPRT
AB  - The UK Five Year Anti-Microbial Resistance Strategy, 2013-2018 was released by the Department of Health (now Department of Health and Social Care, DHSC), with the Department for Environment Food and Rural Affairs (Defra) and Public Health England (PHE), in September 2013. We reviewed progress on the actions in the Strategy requested of the pharmaceutical industry, including the scale and scope of activity underway, the role of various forms of incentives to encourage pharmaceutical innovation, and the scientific, regulatory and commercial challenges experienced by industry and funders. We explored the way government efforts within and beyond the Strategy to addresscommercial viability issues have been viewed by industry, gaps in the approach taken by the Strategy, and opportunities for government to help improve the contribution of biopharma to AMR reduction.Informants recognised the efforts of the Government in responding to the challenges of developing new drugs to tackle AMR, especially the O’Neill Report, development and implementation of the Strategy, the framework of working groups, provision of new research funding, and associatedactions around antibiotic stewardship and infection prevention. The availability of ‘push funding’ (direct support for research) has grown, particularly in the form of multinational public-private partnerships to stimulate research and development for new antibiotics and novel therapies. This type of support was considered more beneficial for small and medium sized companies working on the discovery and pre-clinical stages of drug development than for large pharmaceutical companies. While smaller companies benefit from push incentives, their impact ondrug development was seen as limited unless large pharmaceutical companies, which have the capacity and resources to bring products to market, step in and acquire promising new therapies. Industry informants therefore felt that while push incentives were welcome, additi
AU  - Barlow,J
AU  - Tan,S
PB  - Policy Innovation Research Unit
PY  - 2019///
TI  - Challenges in addressing Anti-Microbial Resistance (AMR) through Drug-related Solutions
UR  - https://piru.ac.uk/
ER  -
Download